I-Mab (IMAB) Competitors

I-Mab (NASDAQ:IMAB) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

Does the MarketBeat Community favor IMAB or DNA?

I-Mab received 38 more outperform votes than Ginkgo Bioworks when rated by MarketBeat users. Likewise, 65.26% of users gave I-Mab an outperform vote while only 46.15% of users gave Ginkgo Bioworks an outperform vote.

Company	Underperform	Outperform
I-Mab	Outperform Votes 62 65.26%	Underperform Votes 33 34.74%
Ginkgo Bioworks	Outperform Votes 24 46.15%	Underperform Votes 28 53.85%

Which has better earnings and valuation, IMAB or DNA?

I-Mab has higher earnings, but lower revenue than Ginkgo Bioworks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$3.27M	65.87	-$206.44M	N/A	N/A
Ginkgo Bioworks	$237.42M	2.09	-$892.87M	-$9.16	-0.93

Do institutionals and insiders hold more shares of IMAB or DNA?

38.4% of I-Mab shares are owned by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are owned by institutional investors. 22.1% of I-Mab shares are owned by insiders. Comparatively, 9.7% of Ginkgo Bioworks shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Which has more volatility and risk, IMAB or DNA?

I-Mab has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500.

Do analysts prefer IMAB or DNA?

I-Mab currently has a consensus target price of $5.50, indicating a potential upside of 108.33%. Ginkgo Bioworks has a consensus target price of $5.77, indicating a potential downside of 32.12%. Given I-Mab's stronger consensus rating and higher probable upside, research analysts plainly believe I-Mab is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Is IMAB or DNA more profitable?

I-Mab has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -298.78%. I-Mab's return on equity of 0.00% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Ginkgo Bioworks	-298.78%	-58.54%	-34.24%

Does the media refer more to IMAB or DNA?

In the previous week, I-Mab and I-Mab both had 1 articles in the media. Ginkgo Bioworks' average media sentiment score of 1.54 beat I-Mab's score of 1.44 indicating that Ginkgo Bioworks is being referred to more favorably in the news media.

Company	Overall Sentiment
I-Mab	Positive
Ginkgo Bioworks	Very Positive

Summary

I-Mab beats Ginkgo Bioworks on 12 of the 16 factors compared between the two stocks.